The Management of Treatment-resistant Depression With Intranasal Esketamine

Welcome to the webinar ‘The Management of Treatment-resistant Depression with Intranasal Esketamine ‘ with Professor David Barton.

This webinar will take place on May 27th 2025, at 7 PM (AEST).

The event is open to all attendees, with exclusive on-demand viewing available for Academy members only. Non-members can purchase live access for $59 AUD by clicking here.

[The Academy Membership gives you access to a range of online interactive courses and webinars throughout the year, with on-demand viewing available for all webinars].

With intranasal esketamine (Spravato®) now listed on the PBS from May 1st for the management of treatment-resistant depression (TRD), this webinar—led by Australian expert Professor David Barton, provides a timely and clinically relevant review of the evidence, indications, and practical use of esketamine in patients with TRD.

As a leading authority in the field, Professor Barton will share his invaluable insights and practical tips to assist clinicians in effectively navigating the challenges associated with TRD.

Topics Include:

• An overview of the burden of TRD
• The evidence for the effectiveness of intranasal esketamine in the management of TRD
• Understanding which patients are appropriate for treatment with esketamine and who may not be a good candidate
• How intranasal esketamine is supplied and administered in clinical practice
• Maintenance therapy and duration of treatment

Don’t miss this opportunity to gain a better understanding of the clinical application of intranasal Esketamine and when and how to refer patients for treatment.

The event will be recorded and available for members to view on demand. 

Upon completion of this event, participants will receive 1.5 CPD towards educational activities.

While our Academy members enjoy exclusive access to a range of courses and webinars (including this event) with their annual membership, we’re pleased to offer you the opportunity to purchase this webinar event individually – ‘The Management of Treatment-resistant Depression With Intranasal Esketamine’.

Speaker Bio: Professor David Barton

Prof David Barton is the founding director of NeuroCentrix, providing care focused on treatment-resistant depression, brain injury and early dementia. For treatment-resistant depression, he offers TMS and Esketamine treatment in Victoria, Queensland and Tasmania. David’s subspecialty is in old-age psychiatry, neuropsychiatry(acquired brain injury) and treatment-resistant mood disorders. He has an extensive background in academia with research areas into ketamine, depression and cardiovascular disease funded through NHMRC grants.

Prof Barton’s other roles include: Director of mental health services at South Eastern Private Hospital, Consultation Liaison Psychiatrist with the Acquired Brain Injury Unit at Caulfield Hospital, Adjunct Professor at the Australian Centre for Heart Health, Senior Research Scientist at the BakerIDI Heart and Diabetes Institute’s Human Neurotransmitter Laboratory, and Honorary Principal Fellow at the University of Melbourne.

Dr Sanil Rege is a consultant psychiatrist and academic, with dual qualifications from the UK and Australia. He is a Fellow of the Royal Australian and New Zealand College of Psychiatrists and a Member of the Royal College of Psychiatrists (UK).

Individual Purchase Link:

‘The Management of Treatment-resistant Depression With Intranasal Esketamine’.